Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 128-133

  Loberg, Robert D ^a   Fielhauer, Jeffery R ^a   Pienta, Brian A ^a   Dresden, Scott ^a   Christmas, Patty ^a   Kalikin, Linda M ^a   Olson, Karin B ^a   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR PROTEIN;

CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; GLEASON SCORE; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ADENOCARCINOMA; ADULT; AGED; ALGORITHM; BLOOD; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KINETICS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK; SALVAGE THERAPY; SURVIVAL; TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1842829885     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.026     Document Type: Article

References (17)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659, 1994.
3. Scher HI, and Heller G: Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55: 323-327, 2000.
4. Duchesne GM, Millar JL, Moraga V, et al: What to do for prostate cancer patients with a rising PSA? A survey of Australian practice. Int J Radiat Oncol Biol Phys 55: 986-991, 2003.
5. Bidart JM, Thuillier F, Augereau C, et al: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45: 1695-1707, 1999.
6. Hanks GE, Hanlon AL, Lee WR, et al: Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34: 549-553, 1996.
7. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
8. Laufer M, Pound CR, Carducci MA, et al: Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55: 309-315, 2000.
9. Stephenson AJ, Aprikian AG, Souhami L, et al: Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59: 652-656, 2002.
10. Goluboff ET, Heitjan DF, DeVries GM, et al: Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 158: 1876-1878, 1997.
11. Nakata S, Takahashi H, Takezawa Y, et al: PSA doubling time in prostate cancer relapsed after endocrine therapy. Nippon Hinyokika Gakkai Zasshi 91: 584-588, 2000.
12. Freedland SJ, Dorey F, and Aronson WJ: Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57: 476-480, 2001.
13. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573, 2002.
14. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
15. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
16. Choo R, DeBoer G, Klotz L, et al: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50: 615-620, 2001.
17. Schmid HP, Morant R, Bernhard J, et al: Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. Eur Urol 43: 28-30, 2003.